Velan Capital Investment Management LP Makes New Investment in Regulus Therapeutics Inc. (NASDAQ:RGLS)

Velan Capital Investment Management LP bought a new position in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 70,000 shares of the biopharmaceutical company's stock, valued at approximately $111,000. Regulus Therapeutics comprises approximately 0.1% of Velan Capital Investment Management LP's investment portfolio, making the stock its 24th largest position. Velan Capital Investment Management LP owned about 0.11% of Regulus Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. PEAK6 LLC bought a new stake in Regulus Therapeutics during the fourth quarter worth $95,000. JPMorgan Chase & Co. lifted its stake in Regulus Therapeutics by 193.4% during the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company's stock worth $124,000 after purchasing an additional 52,059 shares during the last quarter. Barclays PLC lifted its stake in Regulus Therapeutics by 285.2% during the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company's stock worth $132,000 after purchasing an additional 62,549 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Regulus Therapeutics by 20.5% during the fourth quarter. Renaissance Technologies LLC now owns 117,100 shares of the biopharmaceutical company's stock worth $185,000 after purchasing an additional 19,900 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in Regulus Therapeutics by 69.7% during the fourth quarter. Millennium Management LLC now owns 2,192,158 shares of the biopharmaceutical company's stock worth $3,464,000 after purchasing an additional 900,743 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on RGLS. Jones Trading reiterated a "hold" rating and issued a $7.00 price target (down from $8.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Canaccord Genuity Group reiterated a "hold" rating and issued a $11.00 price target (down from $28.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. StockNews.com began coverage on Regulus Therapeutics in a research note on Sunday. They issued a "sell" rating for the company. Wells Fargo & Company reiterated an "equal weight" rating and issued a $9.00 price target on shares of Regulus Therapeutics in a research note on Thursday, May 1st. Finally, Leerink Partnrs cut Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Regulus Therapeutics presently has an average rating of "Hold" and an average price target of $8.50.

Regulus Therapeutics Stock Performance

Shares of RGLS stock opened at $7.87 on Tuesday. The stock has a market cap of $544.87 million, a price-to-earnings ratio of -7.36 and a beta of 0.49. The stock has a 50-day moving average of $3.54 and a 200-day moving average of $2.15. Regulus Therapeutics Inc. has a 1-year low of $0.83 and a 1-year high of $8.20.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.14. Sell-side analysts forecast that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current year.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.